David H. Johnson

David H. Johnson, M.D., serves as Professor and Chair of the Department of Internal Medicine at UT Southwestern Medical Center, holding the R. Ellwood Jones, M.D. Distinguished Professorship in Clinical Education. He specializes in lung cancer as a member of the Division of Hematology-Oncology and maintains active clinical and research roles.

Education:

• Medical Degree: Medical College of Georgia
• Internal Medicine Residency: Mary Imogene Bassett Hospital, Cooperstown, NY
• Medical Oncology Fellowship: Vanderbilt University

Dr. Johnson's research centers on lung cancer biology and therapeutic development for solid tumors. His work bridges molecular mechanisms to clinical applications, with particular focus on angiogenesis inhibitors, targeted therapies, and biomarker identification. He pioneered clinical validation of agents including paclitaxel (Taxol), bevacizumab (Avastin), and erlotinib (Tarceva), establishing foundational treatment protocols now used globally.

His publication trends (2014-2010) reveal strategic shifts toward precision oncology, with increasing emphasis on molecular subtyping (ALK/EGFR pathways), combination therapies, and meta-analyses of treatment efficacy. Key themes include angiogenesis modulation, resistance mechanisms, and optimizing adjuvant/neoadjuvant approaches for resectable disease.

Scientific Awards:

• R. Ellwood Jones, M.D. Distinguished Professorship in Clinical Education

Dr. Johnson has secured substantial research funding enabling large-scale clinical trials and drug development programs. His mentorship extends through ASCO's educational initiatives and UT Southwestern's training programs, though specific student names aren't documented in provided materials. He previously chaired the ABIM Board of Directors and served on the FDA Oncology Drug Advisory Committee, driving regulatory standards for cancer therapeutics.

He collaborates extensively through the Eastern Cooperative Oncology Group (where he chaired the Thoracic Committee), National Comprehensive Cancer Network, and International Association for the Study of Lung Cancer, maintaining influence in national treatment guidelines and quality initiatives like ASCO's QOPI program.